Lymphocytes Subpopulation in Cancer Patients

Cancer Clinical Trial

— CaLym  

Official title:

Lymphocytes Subpopulation and Its Relevance With Tumor Grade and Prognosis in Cancer Patients

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT02516371
• Other study ID #: UC15OISI0093
• Status: Recruiting
• Phase: N/A
• First received: August 1, 2015
• Last updated: August 25, 2015
• Start date: August 2015
• Est. completion date: December 2018

Study information

• Verified date: August 2015
• Source: The Catholic University of Korea
• Contact: Yoon Ho Ko, MD, PhD
• Phone: 82-31-820-3985
• Email: koyoonho[@]catholic.ac.kr
• Is FDA regulated: No
• Health authority: Korea: Ministry for Health and Welfare
• Study type: Interventional

Clinical Trial Summary

This study aims to exam the subpopulation of lymphocytes and evaluate the clinico-pathologic correlations.

Description:

The host's inflammatory response in the tumor microenvironment could effect cancer progression and prognosis. As components of systemic inflammatory response, lymphocytes, neutrophils, and platelets are being recognised to have an important role in carcinogenesis and tumor progression. To date, a number of peripheral blood-derived inflammation-based scores such as the neutrophil-lymphocyte ratio (NLR), platelet- lymphocyte ratio (PLR) and so on have been proposed as prognostic markers in numerous types of cancers. But, very little is known of their impact in subpopulation of lymphocytes. The investigators try to evaluate the activity of lymphocytes in peripheral blood and find out the relationship among clinical prognosis.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 100
• Est. completion date: December 2018
• Est. primary completion date: June 2016
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 20 Years to 80 Years

Eligibility

Inclusion Criteria:

1. cancer patients of Uijeongbu St. Mary's Hospital

2. never treated with chemotherapy

3. Age between 20~80 years-

Exclusion Criteria:

1. treated with chemotherapy before

2. No informed consent form

Study Design

Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science

Related Conditions & MeSH terms

• Cancer

Intervention

Other:
• lymphocyte
To evaluate the subpopulation of lymphocytes in cancer patients

Locations

Country	Name	City	State
Korea, Republic of	Uijeongbu St. Mary's hospital, the Catholic university of Korea	Uijeongbu city	Gyounggido

Sponsors (1)

Lead Sponsor	Collaborator
DERSHENG SUN

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	response rate after cancer treatment with chemotherapy		6 months after chemotherapy	No